Clinical Trial Update: Brodalumab in the Treatment of Immune-Related Adverse Events [Phase 1]

View source ↗

Summary

Phase 1 study of brodalumab for treatment of immune-related adverse events in cancer patients. The trial is currently recruiting across multiple cancer types.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Esophageal Cancer
• Gynecologic Cancer
• Kidney Cancer
• Lung Cancer
• Pancreatic Cancer
• Stomach Cancer
• Thyroid Cancer

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: Brian Henick, MD | Conditions: Breast Cancer, Esophageal Cancer | Phase 1 | Status: RECRUITING